PMID- 28332871
OWN - NLM
STAT- MEDLINE
DCOM- 20170912
LR  - 20210504
IS  - 1530-891X (Print)
IS  - 1530-891X (Linking)
VI  - 23
IP  - 7
DP  - 2017 Jul
TI  - SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF 
      A DYNAMIC DUO.
PG  - 831-840
LID - 10.4158/EP161725.RA [doi]
AB  - OBJECTIVE: This article reviews evidence supporting sodium glucose cotransporter 
      2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitor combination 
      therapy for management of type 2 diabetes mellitus (T2DM). METHODS: We conducted 
      a nonsystematic review of the literature focusing on single-pill or fixed-dose 
      combinations of SGLT2 inhibitors and DPP-4 inhibitors available in the United 
      States. RESULTS: SGLT2 inhibitors and DPP-4 inhibitors have complementary 
      mechanisms of action that address several of the underlying pathophysiologic 
      abnormalities present in T2DM without overlapping toxicities. The combination of 
      these 2 agents has several advantages including a low risk of hypoglycemia, the 
      potential for weight loss, the ability to coformulate into a pill with once-daily 
      administration, and the possibility to use with other classes of glucose-lowering 
      agents. Cardiovascular outcomes trials reported to date support the safety of the 
      DPP-4 class and suggest possible cardioprotective effects for SGLT2 inhibitors - 
      at least based on the first reported study that used empagliflozin. Recent 
      clinical evidence shows that SGLT2 inhibitor/DPP-4 inhibitor therapy is an 
      effective combination for T2DM treatment, providing glycated hemoglobin (HbA1c) 
      reductions of 1.1 to 1.5%, and weight reductions of approximately 2 kg when added 
      to metformin, which is its primary place in therapy. CONCLUSION: The combination 
      of an SGLT2 inhibitor/DPP-4 inhibitor is a safe and effective treatment choice 
      for patients with T2DM who are unable to obtain adequate glycemic control with 
      metformin therapy, cannot use metformin, or have a higher baseline HbA1c. 
      ABBREVIATIONS: BP = blood pressure; CI = confidence interval; CVOT = 
      cardiovascular outcomes; DKA = diabetic ketoacidosis; DPP-4 = dipeptidyl 
      peptidase-4; EXAMINE = EXamination of cArdiovascular outcoMes with alogliptiN 
      versus standard of carE in patients with type 2 diabetes mellitus and acute 
      coronary syndrome; FDA = Food and Drug Administration; HbA1c = glycated 
      hemoglobin; HR = hazard ratio; MACE = major adverse cardiovascular events; 
      SAVOR-TIMI 53 = Saxagliptin Assessment of Vascular Outcomes Recorded in Patients 
      with Type 2 Diabetes Mellitus; SBP = systolic blood pressure; SGLT2 = sodium 
      glucose cotransporter 2; TECOS = Trial to Evaluate Cardiovascular Outcomes after 
      Treatment with Sitagliptin; T2DM = type 2 diabetes mellitus; XR = extended 
      release.
FAU - Lingvay, Ildiko
AU  - Lingvay I
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170323
PL  - United States
TA  - Endocr Pract
JT  - Endocrine practice : official journal of the American College of Endocrinology 
      and the American Association of Clinical Endocrinologists
JID - 9607439
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptides)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Piperidines)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - 3X29ZEJ4R2 (Linagliptin)
RN  - 56HH86ZVCT (Uracil)
RN  - 9100L32L2N (Metformin)
RN  - 9GB927LAJW (saxagliptin)
RN  - HDC1R2M35U (empagliflozin)
RN  - JHC049LO86 (alogliptin)
RN  - PJY633525U (Adamantane)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Adamantane/analogs & derivatives/therapeutic use
MH  - Benzhydryl Compounds/therapeutic use
MH  - Blood Glucose/metabolism
MH  - Canagliflozin/therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Dipeptides/therapeutic use
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Glucosides/therapeutic use
MH  - Humans
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Linagliptin/therapeutic use
MH  - Metformin/therapeutic use
MH  - Piperidines/therapeutic use
MH  - Sitagliptin Phosphate/therapeutic use
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - Treatment Outcome
MH  - Uracil/analogs & derivatives/therapeutic use
EDAT- 2017/03/24 06:00
MHDA- 2017/09/13 06:00
CRDT- 2017/03/24 06:00
PHST- 2017/03/24 06:00 [pubmed]
PHST- 2017/09/13 06:00 [medline]
PHST- 2017/03/24 06:00 [entrez]
AID - S1530-891X(20)35785-2 [pii]
AID - 10.4158/EP161725.RA [doi]
PST - ppublish
SO  - Endocr Pract. 2017 Jul;23(7):831-840. doi: 10.4158/EP161725.RA. Epub 2017 Mar 23.